Datopotamab Deruxtecan side effects: what 639 FDA adverse event reports show

Datopotamab Deruxtecan · Datroway · 14 reaction terms · 436 drug–reaction co-reports · data 2026-09-14

Drug class

Trop-2-directed antibody and topoisomerase inhibitor conjugate

FDA label, Indications wording

Brand names

Datroway

openFDA label

Who reports

639 reports · 60% serious · 138 with death outcome · 82% female

openFDA FAERS counts, all years, deduplication not applied

Used for

DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

FDA label, Indications and Usage

What it is

Datopotamab deruxtecan-dlnk is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. Datopotamab deruxtecan-dlnk is an antibody-drug conjugate (ADC) composed of three components: 1.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 13 strongest signals

Labeled adverse reaction 4Labeled (related wording) 2Reporting / coding artifact 2Not in label — unassessed 5

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Stomatitis (mouth sores)	103	55.8 46.8–66.6ROR 66.3 · χ² 5,496 / p <1e-300	55.2 EB05 46.8 · IC025 +5.1 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 43.9 · 94% clinician	no trial data cached
Disease progression	157	43.7 38.2–50.1ROR 57.7 · χ² 6,543 / p <1e-300	43.5 EB05 38.1 · IC025 +5.0 3/3 methods agree	Reporting / coding artifact	serious PRR 46.7 · 97% clinician	no trial data cached
Polyneuropathy	10	27.6 14.9–51.1ROR 28.0 · χ² 230 / p 2e-52	26.2 EB05 15.0 · IC025 +2.5 3/3 methods agree	Not in label — unassessed	serious PRR 26.9	no trial data cached
Pneumonitis	17	20.6 12.9–33.0ROR 21.2 · χ² 299 / p 3e-67	20.1 EB05 13.1 · IC025 +2.9 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 19.5	no trial data cached
Mucosal inflammation	16	20.2 12.4–32.7ROR 20.6 · χ² 273 / p 2e-61	19.6 EB05 12.5 · IC025 +2.8 3/3 methods agree	Labeled (related wording) related wording	serious PRR 7.8	no trial data cached
Interstitial lung disease	26	17.7 12.1–25.7ROR 18.4 · χ² 393 / p 9e-88	17.4 EB05 12.3 · IC025 +3.1 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 17.2 · 100% clinician	no trial data cached
Metastases to central nervous system	6	15.4 6.9–34.1ROR 15.5 · χ² 67 / p 1e-16	11.8 EB05 4.5 · IC025 +1.5 3/3 methods agree	Not in label — unassessed	serious PRR 15.0	no trial data cached
Dry eye	22	14.9 9.9–22.5ROR 15.4 · χ² 272 / p 2e-61	14.4 EB05 9.7 · IC025 +2.8 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 7.1	no trial data cached
Oral pain	10	14.6 7.9–27.0ROR 14.8 · χ² 114 / p 8e-27	12.9 EB05 6.4 · IC025 +2.1 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Prescribed underdose	8	13.2 6.6–26.2ROR 13.3 · χ² 78 / p 5e-19	10.6 EB05 4.8 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 19.0	no trial data cached
Metastases to liver	7	13.1 6.3–27.4ROR 13.2 · χ² 67 / p 2e-16	10.1 EB05 4.3 · IC025 +1.6 3/3 methods agree	Not in label — unassessed	serious PRR 12.7	no trial data cached
No adverse event	45	8.3 6.3–11.0ROR 8.9 · χ² 285 / p 3e-64	7.9 EB05 6.1 · IC025 +2.5 3/3 methods agree	Reporting / coding artifact	serious PRR 2.9 · 91% clinician	no trial data cached
Osteonecrosis of jaw (jawbone death)	6	7.9 3.6–17.5ROR 8.0 · χ² 30 / p 3e-8	5.4 EB05 2.6 · IC025 +1.0 3/3 methods agree	Not in label — unassessed	serious PRR 7.7	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Disease progression	157	43.7 38.2–50.1ROR 57.7 · χ² 6,543 / p <1e-300	43.5 EB05 38.1 · IC025 +5.0 3/3 methods agree	Reporting / coding artifact	serious PRR 46.7 · 97% clinician	no trial data cached
Stomatitis (mouth sores)	103	55.8 46.8–66.6ROR 66.3 · χ² 5,496 / p <1e-300	55.2 EB05 46.8 · IC025 +5.1 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 43.9 · 94% clinician	no trial data cached
No adverse event	45	8.3 6.3–11.0ROR 8.9 · χ² 285 / p 3e-64	7.9 EB05 6.1 · IC025 +2.5 3/3 methods agree	Reporting / coding artifact	serious PRR 2.9 · 91% clinician	no trial data cached
Interstitial lung disease	26	17.7 12.1–25.7ROR 18.4 · χ² 393 / p 9e-88	17.4 EB05 12.3 · IC025 +3.1 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 17.2 · 100% clinician	no trial data cached
Dry eye	22	14.9 9.9–22.5ROR 15.4 · χ² 272 / p 2e-61	14.4 EB05 9.7 · IC025 +2.8 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 7.1	no trial data cached
Pneumonitis	17	20.6 12.9–33.0ROR 21.2 · χ² 299 / p 3e-67	20.1 EB05 13.1 · IC025 +2.9 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 19.5	no trial data cached
Mucosal inflammation	16	20.2 12.4–32.7ROR 20.6 · χ² 273 / p 2e-61	19.6 EB05 12.5 · IC025 +2.8 3/3 methods agree	Labeled (related wording) related wording	serious PRR 7.8	no trial data cached
Oral pain	10	14.6 7.9–27.0ROR 14.8 · χ² 114 / p 8e-27	12.9 EB05 6.4 · IC025 +2.1 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Polyneuropathy	10	27.6 14.9–51.1ROR 28.0 · χ² 230 / p 2e-52	26.2 EB05 15.0 · IC025 +2.5 3/3 methods agree	Not in label — unassessed	serious PRR 26.9	no trial data cached
Prescribed underdose	8	13.2 6.6–26.2ROR 13.3 · χ² 78 / p 5e-19	10.6 EB05 4.8 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 19.0	no trial data cached
Metastases to liver	7	13.1 6.3–27.4ROR 13.2 · χ² 67 / p 2e-16	10.1 EB05 4.3 · IC025 +1.6 3/3 methods agree	Not in label — unassessed	serious PRR 12.7	no trial data cached
Osteonecrosis of jaw (jawbone death)	6	7.9 3.6–17.5ROR 8.0 · χ² 30 / p 3e-8	5.4 EB05 2.6 · IC025 +1.0 3/3 methods agree	Not in label — unassessed	serious PRR 7.7	no trial data cached
Metastases to central nervous system	6	15.4 6.9–34.1ROR 15.5 · χ² 67 / p 1e-16	11.8 EB05 4.5 · IC025 +1.5 3/3 methods agree	Not in label — unassessed	serious PRR 15.0	no trial data cached
Metastases to lung	3	8.5 2.8–26.4ROR 8.6 · χ² 13 / p 1e-4	4.5 EB05 1.6 · IC025 -0.0 PRR-only: not supported by EBGM or IC	Not in label — unassessed	serious PRR 8.3	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Datopotamab Deruxtecan?

In FDA FAERS, the most frequently co-reported reaction terms for Datopotamab Deruxtecan are stomatitis, interstitial lung disease, dry eye, pneumonitis, mucosal inflammation, oral pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Datopotamab Deruxtecan have an FDA boxed warning?

No. The FDA label retrieved for Datopotamab Deruxtecan has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Datopotamab Deruxtecan causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 2950227c-6230-4ca4-a135-46e44d9424a0, effective 20260527; matched on openfda.generic_name.exact:"DATOPOTAMAB DERUXTECAN")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 14 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.